Evidence map›Paper›PMID 19767587›Full record

ArticleThe Journal of molecular diagnostics : JMD2009

Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Shannon D Barker, Sherri Bale, Jessica Booker, Arlene Buller, Soma Das, Kenneth Friedman, Andrew K Godwin, Wayne W Grody, Edward Highsmith, Jeffery A Kant and 13 more

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Bridging the gap: moving predictive and prognostic assays from research to clinical use.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shannon D BarkerDivision of Laboratory Systems, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, G23, Atlanta, GA 30329-4018, USA. sbarker@cdc.gov
Sherri Bale
Jessica Booker
Arlene Buller
Soma Das
Kenneth Friedman
Andrew K Godwin
Wayne W Grody
Edward Highsmith
Jeffery A Kant
Elaine Lyon
Rong Mao
Kristin G Monaghan
Deborah A Payne
Victoria M Pratt
Iris Schrijver
Antony E Shrimpton
Elaine Spector
Milhan Telatar
Lorraine Toji
Karen Weck
Barbara Zehnbauer
Lisa V Kalman

Funding

Therapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GODWIN, ANDREW K., GOLEMIS, ERICA A. · 1999 to 2013
$33.6M
NCI NIH HHS P50 CA083638PHS HHS U50/CCU300860
6 · The paper itself

Abstract

Well-characterized reference materials (RMs) are integral in maintaining clinical laboratory quality assurance for genetic testing. These RMs can be used for quality control, monitoring of test performance, test validation, and proficiency testing of DNA-based genetic tests. To address the need for such materials, the Centers for Disease Control and Prevention established the Genetic Testing Reference Material Coordination Program (GeT-RM), which works with the genetics community to improve public availability of characterized RMs for genetic testing. To date, the GeT-RM program has coordinated the characterization of publicly available genomic DNA RMs for a number of disorders, including cystic fibrosis, Huntington disease, fragile X, and several genetic conditions with relatively high prevalence in the Ashkenazi Jewish population. Genotypic information about a number of other cell lines has been collected and is also available. The present study includes the development and commutability/genotype characterization of 10 DNA samples for clinically relevant mutations or sequence variants in the following genes: MTHFR; SERPINA1; RET; BRCA1; and BRCA2. DNA samples were analyzed by 19 clinical genetic laboratories using a variety of assays and technology platforms. Concordance was 100% for all samples, with no differences observed between laboratories using different methods. All DNA samples are available from Coriell Cell Repositories and characterization information can be found on the GeT-RM website.

Indexed as

alpha 1-AntitrypsinBRCA1 ProteinBRCA2 ProteinCell LineGenetic TestingHumansMethylenetetrahydrofolate Reductase (NADPH2)Proto-Oncogene Proteins c-retReference Standardsalpha 1-AntitrypsinBRCA1 ProteinBRCA2 ProteinMethylenetetrahydrofolate Reductase (NADPH2)Proto-Oncogene Proteins c-retRET protein, humanSERPINA1 protein, human

Identifiers

PMID19767587
PMCPMC2765754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.